Evidence map›Paper›PMID 41923724›Full record

ReviewReviews in cardiovascular medicine2026

Vascular Protection of Poly(ADP-ribose) Polymerase Inhibitors in the Combination Therapy With Vascular Endothelial Growth Factor Signaling Pathway Inhibitors.

Jie Ma, Caie Li, Wenjuan Wang, Xin Fan, Taotao Wei, Xin Ma, Yingdong Wang, Chuyan Feng, Jing Yu

Abstract readReview
In one paragraph

Review in Reviews in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jie MaDepartment of Hypertension Center, Lanzhou University Second Hospital, 730030 Lanzhou, Gansu, China.ORCID https://orcid.org/0009-0008-0611-462X
Caie LiDepartment of Hypertension Center, Lanzhou University Second Hospital, 730030 Lanzhou, Gansu, China.ORCID https://orcid.org/0009-0000-4228-9330
Wenjuan WangDepartment of Cardiovascular Center, The First People's Hospital of Huzhou City, 313000 Huzhou, Zhejiang, China.ORCID https://orcid.org/0009-0007-9600-9956
Xin FanDepartment of Hypertension Center, Lanzhou University Second Hospital, 730030 Lanzhou, Gansu, China.ORCID https://orcid.org/0009-0004-5165-7261
Taotao WeiDepartment of Hypertension Center, Lanzhou University Second Hospital, 730030 Lanzhou, Gansu, China.ORCID https://orcid.org/0009-0009-8926-5569
Xin MaDepartment of Hypertension Center, Lanzhou University Second Hospital, 730030 Lanzhou, Gansu, China.ORCID https://orcid.org/0000-0003-2230-8973
Yingdong WangDepartment of Hypertension Center, Lanzhou University Second Hospital, 730030 Lanzhou, Gansu, China.ORCID https://orcid.org/0009-0003-3746-7843
Chuyan FengDepartment of Hypertension Center, Lanzhou University Second Hospital, 730030 Lanzhou, Gansu, China.ORCID https://orcid.org/0009-0009-5138-7245
Jing YuDepartment of Hypertension Center, Lanzhou University Second Hospital, 730030 Lanzhou, Gansu, China.ORCID https://orcid.org/0000-0002-4164-764X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Poly(ADP-ribose) polymerase (PARP) family comprises seventeen members that catalyze poly- or mono- adenosine diphosphate (ADP)-ribosylation, a pivotal post-translational modification regulating a wide array of cellular processes, including deoxyribonucleic acid (DNA) repair, apoptosis, protein synthesis, cellular proliferation, and responses to oxidative stress. PARP inhibitors (PARPIs) exhibit selective cytotoxicity in cancers with breast cancer susceptibility gene (

Indexed as

hypertensionPARP1PARPIsvascular endothelial growth factor receptor inhibitors

Identifiers

PMID41923724
PMCPMC13036524

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.